Special Diabetes Program: Funding Opportunities

Below are current funding opportunities supported by the Special Diabetes Program. For other NIH funding opportunities, please see the NIH Guide for Grants and Contracts.

View archived research funding opportunities.

Posted Date Title Open Date (Earliest Submission Date) Application Due Date Full Announcement
1/4/2022 Elucidating the Heterogeneity of Impaired Awareness of Hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed) March 1, 2022 March 31, 2022 RFA-DK-21-036
1/4/2022 Elucidating the Heterogeneity of Impaired Awareness of Hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required) March 1, 2022 March 31, 2022 RFA-DK-21-020
12/3/2021  New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed) May 1, 2022 June 1, 2022 and March 20, 2023 RFA-DK-21-030
8/12/2021 High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01- Clinical Trial Not Allowed)  February 3, 2022 March 3, 2022 RFA-DK-21-017
7/28/2021 Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus (R01 Clinical Trial Required) February 3, 2022 March 3, 2022 RFA-DK-21-018
6/25/2021  Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) January 17, 2022 February 17, 2022 and October 7, 2022 RFA-DK-21-021
5/19/2021  Support for Small Business Innovation Research (SBIR) Development and Testing  of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) February 9, 2022  March 9, 2022 and October 7, 2022 RFA-DK-21-012
5/6/2021  Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed) February 9, 2022  March 9 and October 7, 2022  RFA-DK-21-011
3/17/2021 The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) May 22, 2021 June 22, 2021 and March 9, 2022 RFA-DK-21-004
1/3/2014 Diabetic Complications Consortium Preclinical Testing Program Ongoing Not Applicable DCC-PTP Website